Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans-Dieter Royer

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Molecular Informatics|July 29, 2016
A Microarray Tool Provides Pathway and GO Term AnalysisMartin Koch, Hans-Dieter Royer, Michael Wiese
Oncogene|March 16, 2002
Sp1 as G1 cell cycle phase specific transcription factor in epithelial cellsEdgar Grinstein, Franziska Jundt, Inge Weinert, et al.
International Journal of Clinical Pharmacology and Therapeutics|December 3, 2013
Liposomal cisplatin can overcome chemotherapy resistance of A2780 ovarian cancer cells by inducing the extrinsic apoptotic pathwayDaniel P Stölting, Martin Koch, Michael Wiese, et al.
Biochemical Pharmacology|August 5, 2015
Low molecular weight heparin tinzaparin antagonizes cisplatin resistance of ovarian cancer cellsDaniel Bastian Pfankuchen, Daniel Philipp Stölting, Martin Schlesinger, et al.
Anticancer Research|January 10, 2014
How liposomal Cisplatin overcomes chemoresistance in ovarian tumour cellsDaniel Philipp Stölting, Michaela Borrmann, Martin Koch, et al.
International Journal of Pharmaceutics|January 12, 2010
Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitroMichaela L Krieger, Niels Eckstein, Verena Schneider, et al.
The Journal of Biological Chemistry|February 27, 2003
Splicing factor SRp30c interaction with Y-box protein-1 confers nuclear YB-1 shuttling and alternative splice site selectionUte Raffetseder, Björn Frye, Thomas Rauen, et al.
International Journal of Cancer|January 5, 2002
Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1Martin Janz, Nadia Harbeck, Peer Dettmar, et al.
Journal of Virology|March 31, 2006
Characterization of the recombinant adenovirus vector AdYB-1: implications for oncolytic vector developmentGabriel Glockzin, Klaus Mantwill, Karsten Jurchott, et al.
Oncogene|March 8, 2005
YB-1 facilitates basal and 5-fluorouracil-inducible expression of the human major vault protein (MVP) geneUlrike Stein, Stephan Bergmann, George L Scheffer, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Molecular Informatics|July 29, 2016
A Microarray Tool Provides Pathway and GO Term AnalysisMartin Koch, Hans-Dieter Royer, Michael Wiese
Oncogene|March 16, 2002
Sp1 as G1 cell cycle phase specific transcription factor in epithelial cellsEdgar Grinstein, Franziska Jundt, Inge Weinert, et al.
International Journal of Clinical Pharmacology and Therapeutics|December 3, 2013
Liposomal cisplatin can overcome chemotherapy resistance of A2780 ovarian cancer cells by inducing the extrinsic apoptotic pathwayDaniel P Stölting, Martin Koch, Michael Wiese, et al.
Biochemical Pharmacology|August 5, 2015
Low molecular weight heparin tinzaparin antagonizes cisplatin resistance of ovarian cancer cellsDaniel Bastian Pfankuchen, Daniel Philipp Stölting, Martin Schlesinger, et al.
Anticancer Research|January 10, 2014
How liposomal Cisplatin overcomes chemoresistance in ovarian tumour cellsDaniel Philipp Stölting, Michaela Borrmann, Martin Koch, et al.
International Journal of Pharmaceutics|January 12, 2010
Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitroMichaela L Krieger, Niels Eckstein, Verena Schneider, et al.
The Journal of Biological Chemistry|February 27, 2003
Splicing factor SRp30c interaction with Y-box protein-1 confers nuclear YB-1 shuttling and alternative splice site selectionUte Raffetseder, Björn Frye, Thomas Rauen, et al.
International Journal of Cancer|January 5, 2002
Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1Martin Janz, Nadia Harbeck, Peer Dettmar, et al.
Journal of Virology|March 31, 2006
Characterization of the recombinant adenovirus vector AdYB-1: implications for oncolytic vector developmentGabriel Glockzin, Klaus Mantwill, Karsten Jurchott, et al.
Oncogene|March 8, 2005
YB-1 facilitates basal and 5-fluorouracil-inducible expression of the human major vault protein (MVP) geneUlrike Stein, Stephan Bergmann, George L Scheffer, et al.
Pageof 4